Conventional and Novel Drug Therapeutics to Relief Myocardial Ischemia

Dvir, Danny; Battler, Alexander

doi:10.1007/s10557-010-6254-8

Cited by 6 publications

(5 citation statements)

References 37 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to recent research statins can atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin (Dehghan, Aboofazeli et al 2010;Dvir and Battler 2010).…”

Section: Statinsmentioning

confidence: 99%

“…Ranolazine excreted into both feces and urine. This drug is available as extended-release tablets and usually is prescribed 500 to 1000 mg once daily (FDA 2006;Dvir and Battler 2010).…”

Section: Ranolazinementioning

confidence: 99%

“…Since the f channels are located in the retina as well, the major side effects accompanying ivabradine consumption are visual symptoms like headache, dizziness and luminous/visual phenomenon. Thus, ivabradine may influence driving task (Macher and Levy 2009;Dvir and Battler 2010;Farrer 2010;Fernandez, Tandar et al 2010). …”

Section: Ivabradinementioning

confidence: 99%

See 2 more Smart Citations

Conventional and Novel Pharmacotherapy of Angina Pectoris

Dehghan¹

2011

Angina Pectoris

View full text Add to dashboard Cite

“…Due to recent research statins can atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin (Dehghan, Aboofazeli et al 2010;Dvir and Battler 2010).…”

Section: Statinsmentioning

confidence: 99%

“…Ranolazine excreted into both feces and urine. This drug is available as extended-release tablets and usually is prescribed 500 to 1000 mg once daily (FDA 2006;Dvir and Battler 2010).…”

Section: Ranolazinementioning

confidence: 99%

See 1 more Smart Citation

Conventional and Novel Pharmacotherapy of Angina Pectoris

Dehghan¹

2011

Angina Pectoris

View full text Add to dashboard Cite

“…These damaged but not necrotic cardiomyocytes can still restore their electrophysiological function at the action of drugs [12,13]. At present, the drug treatment of cardiovascular diseases mainly includes three categories: β receptor blockers, nitrates and calcium antagonists, which can dilate blood vessels and reduce myocardial oxygen demand [14]. There are few simulation studies related to antiarrhythmic drugs in MI, which restore the electrophysiological function of myocardial cells by acting on ion channels.…”

Section: Introductionmentioning

confidence: 99%

A simulation study on the effect of antiarrhythmic drugs during myocardial infarction

Liang¹,

He²,

Luo³

et al. 2022

Computing in Cardiology Conference (CinC)

View full text Add to dashboard Cite

Cardiovascular diseases can lead to sudden cardiac death, most of which were caused by arrhythmias induced by myocardial infarction (MI). However, current simulation researches mainly focus on the effect of myocardial fibrosis on wave propagation in tissues, and few studies gave attention to antiarrhythmic drugs for the treatment of MI. Therefore, the aim of this study is to simulate the therapeutic effect of antiarrhythmic drugs. Firstly, this paper constructed the human ventricular cell model in MI based on the TP06 model according to the experimental data. Then, the single-cell model was remodeled by adding the change of ion currents after drug action. We simulated the therapeutic effects of the two drugs (telmisartan and nifedipine) at different concentrations, and compared the changes of parameters before and after the drug action. At the same time, the coaction of the two drugs were simulated on the cell model in MI. The simulation results showed INa agonist telmisartan could increase the maximum depolarization rate of cells in MI, but the drug had no effect on APD. On the contrary, ICaL blocker nifedipine mainly affected the APD and had no effect on the depolarization stage. Under the combined action of the two drugs, APA, RP and APD basically returned to normal values, and dV/dtmax returned to 85% of the normal value.

show abstract

“…An increasingly adopted and promising bradycardic agent is Ivabradine (Iva), which slows heart rate without significantly affecting inotropy [ 22 ], and thus it is widely used in the treatment of angina [ 23 , 24 ]. Unlike beta-blockers, Iva acts by directly closing I f channels, the main responsible for cardiac membrane pacemaker depolarization [ 25 ].…”

Section: Introductionmentioning

confidence: 99%

Chronotropic Modulation of the Source-Sink Relationship of Sinoatrial-Atrial Impulse Conduction and Its Significance to Initiation of AF: A One-Dimensional Model Study

Cacciani

Zaniboni

2015

BioMed Research International

View full text Add to dashboard Cite

Initiation and maintenance of atrial fibrillation (AF) is often associated with pharmacologically or pathologically induced bradycardic states. Even drugs specifically developed in order to counteract cardiac arrhythmias often combine their action with bradycardia and, in turn, with development of AF, via still largely unknown mechanisms. This study aims to simulate action potential (AP) conduction between sinoatrial node (SAN) and atrial cells, either arranged in cell pairs or in a one-dimensional strand, where the relative amount of SAN membrane is made varying, in turn, with junctional resistance. The source-sink relationship between the two membrane types is studied in control conditions and under different simulated chronotropic interventions, in order to define a safety factor for pacemaker-to-atrial AP conduction (SASF) for each treatment. Whereas antiarrhythmic-like interventions which involve downregulation of calcium channels or of calcium handling decrease SASF, the simulation of Ivabradine administration does so to a lesser extent. Particularly interesting is the increase of SASF observed when downregulation G Kr, which simulates the administration of class III antiarrhythmic agents and is likely sustained by an increase in I CaL. Also, the increase in SASF is accompanied by a decreased conduction delay and a better entrainment of repolarization, which is significant to anti-AF strategies.

show abstract

Conventional and Novel Drug Therapeutics to Relief Myocardial Ischemia

Cited by 6 publications

References 37 publications

Conventional and Novel Pharmacotherapy of Angina Pectoris

Conventional and Novel Pharmacotherapy of Angina Pectoris

A simulation study on the effect of antiarrhythmic drugs during myocardial infarction

Chronotropic Modulation of the Source-Sink Relationship of Sinoatrial-Atrial Impulse Conduction and Its Significance to Initiation of AF: A One-Dimensional Model Study

Contact Info

Product

Resources

About